{"product_id":"management-of-urologic-cancer-9781118864623","title":"Management of Urologic Cancer","description":"\u003cb\u003eBook Synopsis\u003c\/b\u003e\u003cbr\u003e\u003cp\u003eManaging urologic cancer by preserving, as opposed to removing, affected tissue, is rapidly becoming the favoured choice for urologists and oncologists. Discover all available options and how to achieve the best possible patient management with this expert guide to the area. The editor, Mark Schoenberg, is an internationally-renown expert in this exciting new area and has recruited an outstanding team featuring some of the leading urologists\/oncologists in North America and Europe to assist him.\u003c\/p\u003e\u003cbr\u003e\u003cbr\u003e\u003cb\u003eTable of Contents\u003c\/b\u003e\u003cbr\u003e\u003cp\u003eList of Contributors xiii\u003c\/p\u003e \u003cp\u003ePreface xvii\u003c\/p\u003e \u003cp\u003e\u003cb\u003eCancer Genetics, Cancer Biology, and Tumor Growth and Metastasis: The Interaction of Cancer and Its Host Environment 1\u003cbr\u003e\u003c\/b\u003e\u003ci\u003eMark C. Markowski and Kenneth J. Pienta\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003eRenal Cell Carcinoma 1\u003c\/p\u003e \u003cp\u003eBladder Cancer 3\u003c\/p\u003e \u003cp\u003eProstate Cancer 6\u003c\/p\u003e \u003cp\u003eReferences 12\u003c\/p\u003e \u003cp\u003e\u003cb\u003ePathological Basis of Tumor Characterization: Cytopathology, Surgical Pathology,  and How Histo]Morphology Informs Treatment Decision Making 19\u003cbr\u003e\u003c\/b\u003e\u003ci\u003eOleksandr N. Kryvenko and Fadi Brimo\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003eThe Kidney 23\u003c\/p\u003e \u003cp\u003eThe Urothelium 27\u003c\/p\u003e \u003cp\u003eThe Testis 29\u003c\/p\u003e \u003cp\u003eReferences 30\u003c\/p\u003e \u003cp\u003e\u003cb\u003eThe Immunobiology of Tumor Ablation\u003c\/b\u003e 33\u003cbr\u003e\u003ci\u003eRafi Kabarriti and Chandan Guha\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003eManipulating the Immune System to Fight Cancer 33\u003c\/p\u003e \u003cp\u003eCan We Take Advantage of Ablative Therapies to Activate the Immune System? 34\u003c\/p\u003e \u003cp\u003eImmunomodulatory Properties of HIFU 35\u003c\/p\u003e \u003cp\u003eImmunomodulatory Properties of Cryotherapy 36\u003c\/p\u003e \u003cp\u003eImmunomodulatory Properties of Radiation Therapy 37\u003c\/p\u003e \u003cp\u003eReferences 38\u003c\/p\u003e \u003cp\u003e\u003cb\u003eComputed Tomography of Urologic Malignancies: The Role of MDCT in Renal Cell Carcinoma and Transitional Cell Carcinoma 41\u003cbr\u003e\u003c\/b\u003e\u003ci\u003eSiva P. Raman and Elliot K. Fishman\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003eIntroduction 41\u003c\/p\u003e \u003cp\u003eMDCT Protocol Design 41\u003c\/p\u003e \u003cp\u003eThree]Dimensional Reconstructions 44\u003c\/p\u003e \u003cp\u003eNeoplasms of the Intrarenal Collecting Systems, Ureters, and Bladder 45\u003c\/p\u003e \u003cp\u003eSolid Renal Parenchymal Lesions 49\u003c\/p\u003e \u003cp\u003eConclusion 55\u003c\/p\u003e \u003cp\u003eReferences 55\u003c\/p\u003e \u003cp\u003e\u003cb\u003eMRI and Metabolic Imaging 59\u003cbr\u003e\u003c\/b\u003e\u003ci\u003eLouise Dickinson, Francesco Fraioli, Athar Haroon, and Clare Allen\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003eMagnetic Resonance Imaging 59\u003c\/p\u003e \u003cp\u003eMRI Sequences 59\u003c\/p\u003e \u003cp\u003eClinical Applications of MRI for Prostate Cancer 61\u003c\/p\u003e \u003cp\u003eClinical Applications of MRI for Renal Cancer 63\u003c\/p\u003e \u003cp\u003eClinical Applications of MRI for Bladder Cancer 64\u003c\/p\u003e \u003cp\u003eNew Advances in MRI 65\u003c\/p\u003e \u003cp\u003eMetabolic Imaging 66\u003c\/p\u003e \u003cp\u003eClinical Applications of PET–CT for Prostate Cancer 69\u003c\/p\u003e \u003cp\u003e\u003cb\u003eActive Surveillance for Low]Risk Prostate Cancer 113\u003cbr\u003e\u003c\/b\u003e\u003ci\u003eLaurence Klotz\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003eIntroduction and Background 113\u003c\/p\u003e \u003cp\u003eRationale 113\u003c\/p\u003e \u003cp\u003eGenetic Features of Low]Grade Prostate Cancer 114\u003c\/p\u003e \u003cp\u003eMetastatic Potential 115\u003c\/p\u003e \u003cp\u003eLimitations of PSA Kinetics 116\u003c\/p\u003e \u003cp\u003eRole of MRI 116\u003c\/p\u003e \u003cp\u003eImplications for Patient Management 117\u003c\/p\u003e \u003cp\u003eEligibility for Surveillance 118\u003c\/p\u003e \u003cp\u003eOutcome of Surveillance 119\u003c\/p\u003e \u003cp\u003eModeling 119\u003c\/p\u003e \u003cp\u003eAS in Practice 121\u003c\/p\u003e \u003cp\u003eConclusions 121\u003c\/p\u003e \u003cp\u003eReferences 122\u003c\/p\u003e \u003cp\u003e\u003cb\u003eTissue]Preserving Surgical Approaches in Urologic Oncology: The Therapeutic Mechanism for Tumor Ablation 127\u003cbr\u003e\u003c\/b\u003e\u003ci\u003eGanesh Kartha and J. Stephen Jones\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003eIntroduction 127\u003c\/p\u003e \u003cp\u003eCryoablation: Extreme Cold for Tumor Necrosis 128\u003c\/p\u003e \u003cp\u003eConclusion 130\u003c\/p\u003e \u003cp\u003eReferences 130\u003c\/p\u003e \u003cp\u003e\u003cb\u003eFocal Therapy for Prostate Cancer: An Evidence]Based Approach to Tissue]Preserving Strategies 133\u003cbr\u003e\u003c\/b\u003e\u003ci\u003eKara L. Watts, Yaalini Shanmugabavan, Victoria Chernyak, and Hashim Uddin Ahmed\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003eIntroduction 133\u003c\/p\u003e \u003cp\u003eKey Concepts in FT for PCa 134\u003c\/p\u003e \u003cp\u003eTissue]Preserving FTs 135\u003c\/p\u003e \u003cp\u003eCryotherapy 135\u003c\/p\u003e \u003cp\u003eHIFU 137\u003c\/p\u003e \u003cp\u003eSalvage Focal\/Hemiablation HIFU 140\u003c\/p\u003e \u003cp\u003eIRE 141\u003c\/p\u003e \u003cp\u003eRadiation 142\u003c\/p\u003e \u003cp\u003eAdditional Therapies 143\u003c\/p\u003e \u003cp\u003eImplications for Research 144\u003c\/p\u003e \u003cp\u003eConclusions 144\u003c\/p\u003e \u003cp\u003eReferences 145\u003c\/p\u003e \u003cp\u003e\u003cb\u003eThe Modern Basis for Nephron]Sparing Surgery in Patients with Renal Cancer: Biologic Heterogeneity, the Significance of Tumor Biopsy, and the Changing Roles of Partial Nephrectomy and Tumor Ablation 151\u003cbr\u003e\u003c\/b\u003e\u003ci\u003eJeffrey J. Tomaszewski, Robert G. Uzzo, and David Y.T. Chen\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003eIntroduction 151\u003c\/p\u003e \u003cp\u003ePrincipal Treatment Options for SRMs and the Basis for Nephron Preservation 152\u003c\/p\u003e \u003cp\u003eComparative Effectiveness of Radical versus NSS 153\u003c\/p\u003e \u003cp\u003eRationale for Ablative Therapies 154\u003c\/p\u003e \u003cp\u003eTreatment Trends for Stage I RCC 157\u003c\/p\u003e \u003cp\u003eThe Role of RMB 158\u003c\/p\u003e \u003cp\u003eChallenges Posed by Intratumoral Heterogeneity 161\u003c\/p\u003e \u003cp\u003eConclusions 161\u003c\/p\u003e \u003cp\u003eReferences 162\u003c\/p\u003e \u003cp\u003e\u003cb\u003eBladder]Preserving Strategies in the Treatment of Urothelial Cancer: The Disease Spectrum and the Dawn of Molecular Surgical Guidance 169\u003cbr\u003e\u003c\/b\u003e\u003ci\u003eStephan Kruck and Arnulf Stenzl\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003eAugmented Cystoscopy 170\u003c\/p\u003e \u003cp\u003eFiber]Optic Probe Technology 171\u003c\/p\u003e \u003cp\u003eConclusion 172\u003c\/p\u003e \u003cp\u003eReferences 172\u003c\/p\u003e \u003cp\u003e\u003cb\u003eImage]Guided Thermal Ablation of Adrenal Malignancies 175\u003cbr\u003e\u003c\/b\u003e\u003ci\u003eKyungmouk Steve Lee, Bradley B. Pua, and Stephen B. Solomon\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003eIntroduction 175\u003c\/p\u003e \u003cp\u003eClinical Results 175\u003c\/p\u003e \u003cp\u003ePreprocedural Evaluation 176\u003c\/p\u003e \u003cp\u003eTechnical Considerations 178\u003c\/p\u003e \u003cp\u003eRFA 178\u003c\/p\u003e \u003cp\u003eMicrowave Ablation 179\u003c\/p\u003e \u003cp\u003eCryoablation 180\u003c\/p\u003e \u003cp\u003eComplications 180\u003c\/p\u003e \u003cp\u003eFollow]up 181\u003c\/p\u003e \u003cp\u003eConclusion 182\u003c\/p\u003e \u003cp\u003eReferences 182\u003c\/p\u003e \u003cp\u003e\u003cb\u003eManaging Penile Cancer: Integrating Tissue Preservation, Energy]Based Therapeutics, and Surgical Reconstruction 185\u003cbr\u003e\u003c\/b\u003e\u003ci\u003eArthur L. Burnett\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003eIntroduction 185\u003c\/p\u003e \u003cp\u003eDescription 186\u003c\/p\u003e \u003cp\u003eDiagnosis and Staging 186\u003c\/p\u003e \u003cp\u003eTreatment 189\u003c\/p\u003e \u003cp\u003eReferences 193\u003c\/p\u003e \u003cp\u003e\u003cb\u003eTestis Cancer: Testis]Sparing Cancer Surgery 199\u003cbr\u003e\u003c\/b\u003e\u003ci\u003eNilay M. Gandhi and Pravin K. Rao\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003eIntroduction 199\u003c\/p\u003e \u003cp\u003eImaging of Testicular Tumors 199\u003c\/p\u003e \u003cp\u003eBilateral Tumors 201\u003c\/p\u003e \u003cp\u003eThe Advent of Testis]Sparing Surgery 201\u003c\/p\u003e \u003cp\u003eConcerns about TSS 201\u003c\/p\u003e \u003cp\u003eIndications for TSS 204\u003c\/p\u003e \u003cp\u003ePreoperative Considerations and Surgical Technique 204\u003c\/p\u003e \u003cp\u003ePostoperative Care and Follow]Up 207\u003c\/p\u003e \u003cp\u003eConsiderations Regarding Surgical Technique 207\u003c\/p\u003e \u003cp\u003eOutcomes of TSS 208\u003c\/p\u003e \u003cp\u003eSummary 209\u003c\/p\u003e \u003cp\u003eReferences 210\u003c\/p\u003e \u003cp\u003e\u003cb\u003eNanotechnology: An Evolution in Tissue Preservation and Focal]Targeted Oncologic Therapy 213\u003cbr\u003e\u003c\/b\u003e\u003ci\u003eKara L. Watts and Joshua M. Stern\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003eIntroduction 213\u003c\/p\u003e \u003cp\u003eIntroduction to Nanotechnology 214\u003c\/p\u003e \u003cp\u003eTypes of Nanoparticles 214\u003c\/p\u003e \u003cp\u003eDelivery and Use of Nanoparticles 217\u003c\/p\u003e \u003cp\u003eNanotechnology in Prostate Cancer 219\u003c\/p\u003e \u003cp\u003eImaging in Prostate Cancer 219\u003c\/p\u003e \u003cp\u003eTherapeutics in Prostate Cancer 221\u003c\/p\u003e \u003cp\u003eNanotechnology in Renal Cancer 223\u003c\/p\u003e \u003cp\u003eNanotechnology in Other Urologic Cancers 224\u003c\/p\u003e \u003cp\u003eLimitations of Nanoparticles 224\u003c\/p\u003e \u003cp\u003eFuture Directions and Conclusions 225\u003c\/p\u003e \u003cp\u003eReferences 226\u003c\/p\u003e \u003cp\u003e\u003cb\u003eTrial Design Issues in the Study of Focal Therapy in Prostate and Kidney Cancer 233\u003cbr\u003e\u003c\/b\u003e\u003ci\u003eJohn B. Eifler and David F. Penson\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003eIssues around Endpoints in Studies of Focal Therapy 234\u003c\/p\u003e \u003cp\u003eIssues around Defining the Study Population and the Control Arms of Comparative Studies in Focal Therapy 237\u003c\/p\u003e \u003cp\u003eIssues around Selecting the Optimal Study Design in Focal Therapy 238\u003c\/p\u003e \u003cp\u003eConclusion 238\u003c\/p\u003e \u003cp\u003eReferences 239\u003c\/p\u003e \u003cp\u003eIndex 000\u003c\/p\u003e","brand":"John Wiley and Sons Ltd","offers":[{"title":"Default Title","offer_id":49406937137495,"sku":"9781118864623","price":117.85,"currency_code":"GBP","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0817\/1739\/5799\/files\/9781118864623.jpg?v=1730497618","url":"https:\/\/bookcurl.com\/products\/management-of-urologic-cancer-9781118864623","provider":"Book Curl","version":"1.0","type":"link"}